Related Experiment Videos
[New cytostatic drugs. Status: 1986]
15. Medizinische Klinik und Institut für Medizinische Onkologie und Hämatologie, Klinikum der Stadt Nürnberg.
Abstract:
In oncology phase-II studies are planned for testing antitumor activity in a series of malignant tumors. Most important is the development of drugs from entirely new classes of chemicals, fermentation products etc. Clinical research with analogues of known cytotoxic drugs aims at broader spectra of activity and at decreased toxicity in an attempt to avoid, for example, the cardiac toxicity of the anthracyclines or the renal and gastrointestinal toxicities of cis-platinum.
Insights
Phase II oncology studies will assess novel anticancer drugs, including new chemical classes and fermentation products. Research also focuses on improving existing cytotoxic drugs to broaden their effectiveness and reduce side effects.
Area of Science:
- Oncology
- Drug Discovery
- Medicinal Chemistry
Context:
- Phase II clinical trials are crucial for evaluating antitumor activity.
- Development of novel therapeutic agents is essential in cancer treatment.
- Existing cytotoxic drugs present challenges like cardiotoxicity and nephrotoxicity.
Purpose:
- To test the antitumor activity of new drug candidates in phase II oncology studies.
- To explore novel drug classes, including chemical entities and fermentation products.
- To develop analogues of known cytotoxic drugs with improved safety and efficacy profiles.
Summary:
- Phase II studies are designed to evaluate the efficacy of potential anticancer drugs against various malignant tumors.
- Research efforts are directed towards discovering drugs from novel chemical classes and fermentation-derived compounds.
- Clinical investigations aim to create analogues of established cytotoxic agents to enhance their spectrum of activity and minimize toxicities, such as cardiac, renal, and gastrointestinal issues associated with anthracyclines and cisplatin.
Impact:
- Accelerating the development of new cancer therapies.
- Providing safer and more effective treatment options for cancer patients.
- Expanding the therapeutic arsenal against a range of malignancies.